Pharmacogenetics

Following approval by the Innovation Design Authority and the NHS Executive Leadership Group, the Scottish Government announced funding (£1.9m) for the programme in March 2025. 

The pre implementation phase of the programme commenced in April 2025. 

This programme includes 2 genetic tests: 

1. A lab-based test (CYP2C19 Genotype Testing) to identify patients who are resistant to Clopidogrel, preventing patients being prescribed a medication that wont work for them.
   
   
2. A Point of Care Test (POCT) for neonates to prevent the permanent hearing loss caused by gentamicin-induced ototoxicity.